States can build public vaccine factories as VICP backup — SkimNews
Get the Geopolitics newsletter
Daily geopolitics — wars, elections, sanctions, the diplomatic moves that move markets. Free.
- The Trump administration is reportedly considering changes to the Vaccine Injury Compensation Program (VICP), which has protected U.S. vaccine supply for 40 years — potentially removing childhood vaccines or making autism-related claims compensable.
- Health Secretary Robert F. Kennedy Jr. and a chief adviser may pull vaccines being made optional under federal recommendations from VICP coverage, raising legal liability for producers.
- The VICP awarded compensation to roughly 10,500 claimants out of more than 5 billion vaccine doses distributed between 2006 and 2024 — about one award per 1 million doses.
- Adding autism-related claims to VICP could produce $100 billion in awards against a fund balance of just $4 billion — approaching 20 times the total VICP has paid out over its entire history.
- Massachusetts' MassBiologics, a public vaccine manufacturer created in 1894 and now operated by UMass Chan Medical School, remains the nation's only nonprofit vaccine producer and currently makes the tetanus-diphtheria vaccine distributed nationwide.
- State-owned production facilities would be shielded by sovereign immunity and may be exempt from FDA regulation, since Congress empowered the FDA to regulate "persons," not states.
- The 1980s crisis that prompted VICP's creation saw only one U.S. whooping-cough vaccine maker remain by 1984, with prices raised tenfold — the supply shock Congress designed VICP to prevent.
Why it matters: Adding autism-related claims to VICP could mean $100 billion in awards against a $4 billion fund balance — roughly 20 times all payouts in the program's history. State-owned factories, shielded by sovereign immunity and potentially exempt from FDA oversight, offer a legal path private manufacturers cannot access.
Ask SkimNews
